MediSieve CEO Dr George Frodsham attended ASGCT 2026 in Boston, connecting with researchers and industry leaders across the rapidly evolving gene therapy field.

CEO George Frodsham will showcase their groundbreaking Magnetic Blood Filtration technology to over 500 healthcare companies and venture capitalists.

Dr George Frodsham, CEO of MediSieve, was invited as a panelist at the Jawdrop Life Sciences Summit to discuss ageing, pandemics, and antimicrobial resistance alongside other distinguished experts.

MediSieve has been busy presenting and demonstrating its technology to some of the world's leading investors throughout March.

In March the company engaged and connected with the communities of UCL and that of the Royal Academy of Engineering by participating in their events.

MediSieve’s first product targets IL-6 cytokine to treat various hyperinflammation condition like Sepsis, COVID-19, and Cytokine Release Syndrome.

MediSieve is presenting virtually at the Biotech Showcase™ 2022 conference.

MediSieve presented the company’s journey at the launch of LBS's I2M Programme and later listened to an excellent panel with LBS alumni.

MediSieve participated in the Life Sciences RoundTable alongside Imperial College London and Novartis.

Throughout September 2020 MediSieve took part in UK Sepsis Trust's initiative Cycle4Sepsis.

MediSieve has joined a 10-week data analysis program run by the London Business School,

MediSieve held a charity bake sale to support the UK Sepsis Trust on the World Sepsis Day.

MediSieve has been included in the round-up of the most exciting medical technology companies who presented at the event.

On September 27, 2017, George Frodsham, founder and CEO of MediSieve, is presenting at the TCT Show.